Introduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Patient-focused investments and acquisitions Innovation at Boston Scientific ranges from discovering new FARAPULSE acquisition: treatments to extending the reach of solutions that are making Improving care with emerging technology a significant difference in patients' quality of life. In a dynamic health care landscape, life-changing ideas can come from Millions of patients around the world are affected by atrial fibrillation (AF), companies big and small. Through our venture portfolio and a serious medical condition that requires treatment to prevent stroke. strategic acquisitions, we invest in early-stage and commercial AF is often treated through a procedure called cardiac ablation, which companies to identify technologies that expand our ability uses heat or cold to destroy the heart tissue causing rapid and irregular to address complicated diseases and conditions. heartbeats, but it can put surrounding tissue at risk. Our search for various Learn more about Boston Scientific acquisitions on our website. technology led us to acquire Farapulse, a company we've been investing in since 2014. Farapulse makes an alternative treatment known as pulsed field ablation (PFA), which uses tissue-selective technology that allows physicians to block abnormal heartbeats with precision and reduce the risk of complications associated with conventional ablation procedures. Boston Scientific acquired Farapulse in 2021 and last year successfully completed enrollment for an investigational device exemption (IDE) clinical trial for the Farapulse™ PFA Systems1 in the United States. The trial will compare the Farapulse™ PFA System with the standard-of-care ablation for the treatment of paroxysmal, or intermittent, AF. “ At Boston Scientific, we have a responsibility to patients and their providers to achieve the best possible outcomes in care. We are investing in emerging technology like PFA to do just that.” Kenneth Stein, MD senior vice president and global chief medical officer 1 CAUTION. Investigative device. The Farapulse Pulsed Field Ablation System is limited by U.S. law to investigative use only and not available for sale. 16 2022 Performance Report